Navigation Links
NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

g postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... DOR BioPharma, Inc. (DOR or the ... announced today that investigators at the Fred Hutchinson Cancer ... in Bone Marrow Transplantation in which they ... or BDP) decreases non-infectious inflammation of the lung in ...
... 29 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the ... and Earth Technology Development Corp. Ltd.,("China RainEarth") attended the ... , A good marketing strategy ... products. In the forum, participants explored various marketing,strategies and ...
... Associates | Architects ( www.kornberg.com ) has been ... Cognitive & Neurobiological Imaging Center. Ken Kornberg, president and ... Stanford University since 1980 and has completed 20 ... the two-story, 32,000 square-foot office building for the Stanford Linear ...
Cached Biology Technology:DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6RainEarth (RNER) Continues to Expand its Marketing Force in China 2RainEarth (RNER) Continues to Expand its Marketing Force in China 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2
(Date:4/14/2014)... scientists are continuing to unravel the molecular changes that ... respiratory infections. , When the bacterium Yersinia pestis enters ... is 100 percent fatal if untreated. The way in ... and kills people in a matter of days has ... study demonstrating that the presence of a protein called ...
(Date:4/14/2014)... families face the decision of whether to get ... the decision can be even more challenging. Now, ... ownership decisions in families of children with autism ... the parents reported the benefits of dog ownership ... children to learn responsibility. , "Children with autism ...
(Date:4/14/2014)... feel when an elevator zips you up multiple floors in ... carried you all the way up to the top of ... That,s similar to what many fish experience when they travel ... change in pressure is simply too big, too fast, and ... in the March issue of the journal Fisheries , ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... trial called the "Evaluate the Clinical use of vitamin ... Angela Cheung and colleagues at the University of Toronto ... did not protect against age-related bone mineral density (BMD) ... Medicine , the findings also suggest that vitamin K1 ...
... University Medical Center has suggested an entirely new way to explain ... have debated for the past 100 years about why -- when ... object -- the flash is perceived to lag behind the position ... to present a completely different way of thinking about how this ...
... their chimpanzee relatives, bonobo societyin which females enjoy a ... image. While chimpanzee males frequently band together to hunt ... to restrict what meat they do eat to forest ... to a study, reported in the October 14th issue ...
Cached Biology News:Duke team explains a longtime visual puzzler in new way 2Despite 'peacenik' reputation, bonobos hunt and eat other primates too 2
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
Biology Products: